Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of Time-restricted Eating on Nutrient Absorption in Healthy Adults

22 de junio de 2022 actualizado por: Claire E. Berryman, Florida State University
This 2-period, crossover, controlled-feeding trial will investigate the effects of early time-restricted eating (8am-2pm), compared to a control eating timeframe (8am-8pm), on energy and macronutrient digestibility, the thermic effect of food (TEF), postprandial blood metabolites, 24 h glucose concentrations, glycemic variability, intestinal hydrogen gas production, gastrointestinal transit time, and microbiome composition. This study will also seek to determine factors that may predict intestinal absorption efficiency (i.e., digestibility) including the microbial composition of stool, fasting and postprandial metabolomics, gastrointestinal transit time, thermic effect of food, 24 h glucose concentrations and variability, and hydrogen gas production.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

The obesity epidemic is well documented, and despite a complex etiology influenced by genetic, physiological, psychological, social, behavioral, and environmental factors, obesity seems to be the result of energy imbalance, where energy intake exceeds energy expenditure, regardless of the internal and external influences. Studies aiming to quantify and manipulate modulators of energy balance, including gastrointestinal (GI) energy absorption rates (i.e., digestibility), are crucial for reducing the incidence of overweight and obesity and improving overall human health. Despite considerable interindividual variability in the amount of ingested energy that is absorbed (~87-98% of ingested energy) by the gastrointestinal tract, generalized equations are used to calculate individual energy intake requirements, and the factors that contribute to such variability, including meal-timing, are largely unknown.

The proposed study seeks to determine the effects of restricting the eating window to 6-h (early time-restricted eating) as compared to a control eating window of 12 h on energy and macronutrient digestibility, thermic effect of food (TEF), postprandial blood metabolites (triglyceride, insulin, glucose, fructose, galactose, inositol, and sorbitol), 24 h glucose concentrations and glycemic variability, intestinal hydrogen gas production, microbiome composition, and gastrointestinal transit time in response to a controlled, energy balanced diet. In addition, this project will determine whether energy digestibility can be predicted from biological and physiological factors such as gut microbiota composition, gastrointestinal transit time, 24-h glucose concentrations, and postabsorptive and postprandial metabolomic profiles.

Participants will be randomized to early TRE (6-h feeding window, 8am-2pm) or a control eating schedule (12-h feeding window, 8am-8pm) and consume a controlled, energy balance diet (breakfast, lunch, dinner, snacks, and beverages) for 9 consecutive days before crossing over to the other intervention after at least a 3-wk washout for females (to control for hormonal fluctuations) and at least a 2-wk washout for males. Participants will collect stool and urine during each feeding phase. Gross energy content (heat combustion by bomb calorimetry) of the diet, stool, and urine samples will be used to calculate energy digestibility (diet gross energy - stool gross energy) and metabolizable energy. Factors that may mediate and/or predict energy digestibility efficiency, including gastrointestinal microbial composition, transit time, and gas production, fasting and postprandial metabolites, continuous glucose concentrations, and thermogenesis will be assessed.

Tipo de estudio

Intervencionista

Inscripción (Actual)

17

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Tallahassee, Florida, Estados Unidos, 32306
        • Florida State University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 45 años (Adulto)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 20-45 years old
  • Normal weight or overweight (18.5 to 29.9 kg/m2)
  • Not taking any probiotics for 4 weeks prior to and throughout the entire study
  • Willing to refrain from smoking, vaping, chewing tobacco, and dietary supplement use throughout the study
  • Willing to consume a controlled diet for 9 consecutive days on 2 different occasions (18 days total) and collect all urine and fecal output for 3-5 days during each occasion
  • Pass the blue dye gastrointestinal tracer (given at screening) within 72 hours of administration

Exclusion Criteria:

  • Metabolic or cardiovascular abnormalities, gastrointestinal disorders, prior bariatric surgery, malabsorption, or any condition that interferes with metabolism (e.g., kidney disease, diabetes, cardiovascular disease, etc.)
  • Suspected or known strictures, fistulas, or physiological/mechanical gastrointestinal obstruction
  • Present condition of alcoholism, anabolic steroids, or other substance abuse issues
  • Women who are pregnant, lactating, planning to become pregnant, or who have an irregular menstrual cycle in the past 6 months
  • Weight fluctuations ± 5% of body weight in the last 6 months
  • Allergies or intolerance to foods included in the controlled diet
  • Any use of antibiotics, except topical antibiotics, within 3 months of study participation
  • Colonoscopy within 3 months of study participation
  • Use of laxatives, stool softeners, or anti-diarrheal medications more than once a week within 4-weeks of study enrollment

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: early time-restricted eating (eTRE)
Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 6-h window in the morning hours (e.g., 8:00 AM - 2:00 PM)
A diet meeting the participant's weight maintenance energy needs will be provided.
Experimental: control eating schedule (CON)
Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 12-h window in the morning hours (e.g., 8:00 AM - 8:00 PM)
A diet meeting the participant's weight maintenance energy needs will be provided.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Energy digestibility
Periodo de tiempo: Days 4-9
Calculated as gross energy of the diet (kcals) - gross energy excreted in stool (kcals)
Days 4-9

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fat digestibility
Periodo de tiempo: Days 4-9
Calculated as fat content of the diet - fat content excreted in stool
Days 4-9
Carbohydrate digestibility
Periodo de tiempo: Days 4-9
Calculated as carbohydrate content of the diet - carbohydrate content excreted in stool
Days 4-9
Protein digestibility
Periodo de tiempo: Days 4-9
Calculated as protein content of the diet - protein content excreted in stool
Days 4-9
Metabolizable energy
Periodo de tiempo: Days 4-9
Calculated as gross energy of the diet (kcals) - gross energy excreted in urine and stool (kcals)
Days 4-9
Metabolizable protein
Periodo de tiempo: Days 4-9
Calculated as protein content of the diet - protein excreted in urine and stool
Days 4-9
Postabsorptive and postprandial plasma metabolites
Periodo de tiempo: Day 6
Plasma metabolites will be measured using gas chromatography coupled with mass spectrometry in the postabsorptive state and following a standardized meal (1 hour, 2 hours, 3 hours, and 4 hours after meal intake).
Day 6
Gut microbiome
Periodo de tiempo: Day 6
Microbiota composition and diversity will be determined using 16S rRNA gene sequencing.
Day 6
Gastrointestinal transit time
Periodo de tiempo: Day 6
A gas-sensing capsule will be ingested to measure transit time in the gastrointestinal tract.
Day 6
Gastrointestinal gas production
Periodo de tiempo: Day 6
A gas-sensing capsule will be ingested to measure hydrogen, carbon dioxide, and oxygen production in the gastrointestinal tract.
Day 6
Gastrointestinal temperature
Periodo de tiempo: Day 6
A gas-sensing capsule will be ingested to measure temperature in the gastrointestinal tract.
Day 6
24-h glucose concentrations
Periodo de tiempo: Days 1-8
A continuous glucose monitor will be used to collect and assess 24-h glucose concentrations.
Days 1-8
24-h glucose variability
Periodo de tiempo: Days 1-8
A continuous glucose monitor will be used to collect and assess 24-h glucose variability.
Days 1-8
Thermic effect of food
Periodo de tiempo: Day 6
Indirect calorimetry measures will be collected in the resting state and for 4 hours (15-30, 45-60, 75-90, 105-120, 165-180, and 225-240 minutes) following the consumption of a standardized meal.
Day 6

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Claire E Berryman, Ph.D., Florida State University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de diciembre de 2021

Finalización primaria (Actual)

10 de junio de 2022

Finalización del estudio (Actual)

10 de junio de 2022

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2021

Primero enviado que cumplió con los criterios de control de calidad

3 de mayo de 2021

Publicado por primera vez (Actual)

7 de mayo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de junio de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

22 de junio de 2022

Última verificación

1 de junio de 2022

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • STUDY00001564

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir